Retrying immunotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether giving immunotherapy again as a second treatment can help people with advanced stomach or gastroesophageal junction cancer. It reviews past patient data to see how well this approach works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic stomach or gastroesophageal junction cancer confirmed by biopsy.
- You received at least 2 cycles of an immunotherapy drug (like PD-1 or PD-L1 inhibitors) as your first treatment.
- You received at least 2 cycles of an immunotherapy-based second treatment.
- You are in good physical condition (able to care for yourself, ECOG score 0 or 1).
- You do not have another cancer (other than this one) in the past 5 years.
- You did not receive radiation therapy as part of your second treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of two drugs (QL1706, which is an immunotherapy, and paclitaxel, a chemotherapy drug) plus a targeted drug called bevacizumab, for people with advanced stomach cancer that has grown despite a first treatment that included immunotherapy. It aims to see if 'rechallenging' with immunotherapy in a different combination can help control the cancer.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
Hear when a new Gastric Cancer, Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.